$50m investment and rebrand unveiled at J.P. Morgan Healthcare Conference as part of new global growth strategy.
RALEIGH, NC, January 9, 2023: ProPharma Group – the end-to-end, global provider of regulatory, clinical and compliance services for the pharmaceutical, biotechnology and medical device industries – today launched the Research Consulting Organization (RCO) model, a new type of research consulting and clinical service for biotech, pharma and device innovators to deliver bespoke solutions that bring life-saving drugs to market sooner and more cost effectively.
Announced at the opening of this year’s J.P. Morgan Healthcare Conference, the new model will provide innovators with unmatched access to the world’s leading strategists to de-risk their most critical programs and provide sponsors and physicians with the greatest probability of success. By drawing on its expertise across areas including regulatory strategy, clinical development, quality and compliance, pharmacovigilance and medical information, the model also harnesses an increased scale of operations and data-driven insights to drive greater R&D productivity for clients, cutting delays and budget overruns.
ProPharma is introducing itself to a global audience for the first time as the world's largest Research Consulting Organization, underpinned by a $50m investment. The new strategy and operating model are further supported by the launch of a global re-brand, including a modern look and feel for the organization and overarching ProPharma brand. In addition to new branding, existing and prospective clients will enjoy an enhanced digital experience across engagement channels including the website (www.propharmagroup.com), social media and client-facing communications.
According to a new White Paper released today, ProPharma is also taking a bold leadership position in a dynamic industry and is confident the life sciences industry at large will benefit from its groundbreaking RCO model. Fit-for-purpose, and built-for-the-future, the RCO will benefit clients of all sizes, including emerging clients who may have received less attention in the past; growing clients who require partnership and expertise to achieve momentum and scale; and established clients who require experienced global capabilities coupled with scaled operational support.
The White Paper references major consolidation and huge growth among CROs in recent years. This trend, caused by organizations seeking to secure the biggest returns for shareholders, has left smaller and medium players contending with lesser resources to recruit patients to trial, drastic delays to the approval of medicines and treatments and costly budget overruns.
The White Paper further outlines that smaller programs, for example those developing molecules for rare and orphan diseases, innovative new devices or cell therapies, need bespoke solutions that are readily available and more effectively delivered through the new RCO approach.
Michael Stomberg, CEO of ProPharma Group, said: “The Research Consulting Organization (RCO) model is designed to lead to optimal results and provide a real alternative for sponsors who don’t fit the mold. While we’re unveiling this new model today, the reality is that we’ve been planning this for some time, in light of feedback from our customers.
“The RCO is a fit-for-purpose, built-for-the-future solution that gives the resources our customers need at every point in their development continuum, no matter their size. This innovative approach will act as the umbrella over distinct service offerings, allowing us to provide deep scientific and technical expertise – including access to some of the world's leading experts – to help sponsors get life-saving drugs and treatment to market faster and more cost-effectively.
“As part of the new operating model and our global re-brand, ProPharma’s purpose, mission and vision are evolving to ultimately further help improve the health and safety for patients around the world.”
Clarity for ProPharma
For the past 20 years, ProPharma has improved the health and wellness of patients by
providing advice and expertise that empowers biotech, med device, and pharmaceutical
organizations of all sizes to confidently advance scientific breakthroughs and introduce new
therapies. As the world’s largest RCO (Research Consulting Organization), ProPharma
partners with its clients through an advise-build-operate model across the complete product
lifecycle. With deep domain expertise in regulatory sciences, clinical research solutions,
quality and compliance, pharmacovigilance, medical information, and R&D technology,
ProPharma offers an end-to-end suite of fully customizable consulting solutions that de-risk
and accelerate our partners’ most high-profile drug and device programs.
January 9, 2023
ProPharma Group announced that its wholly-owned subsidiary ProPharma Group The Netherlands B.V., has obtained an authorization for a manufacturing and import (MIA) license. Following successful...
January 9, 2023
The Weinberg Group (now ProPharma Group), the leading FDA consulting firm, is pleased to announce that Steve Jensen has joined us as Senior Vice President, Head of Regulatory Consulting. Steve has...
January 9, 2023
ProPharma Group today announces the opening of a new medical information contact center in Fort Washington, Pennsylvania to accommodate our growing business. ProPharma Group, a provider of...